Fig. 4From: Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United KingdomNet benefit threshold: midostaurin versus standard of care. CE MIDO cost-effectiveness of midostaurin, CE SOC cost-effectiveness of standard of careBack to article page